Eisai’s Leqembi subcutaneous initiation treatment approved in China
Eisai Co., Ltd. says its Leqembi (Lecanemab) subcutaneous formulation for initiation treatment in early Alzheimer’s disease has been approved in China.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.